KR100846100B1 - Manufacturing method and that creation water of the allergy treatment composition which uses the vitis amurensis ruprecht - Google Patents

Abstract

A method for preparing a composition for treating allergy is provided to obtain the composition from an extract of Vitis amurensis Ruprecht, which shows excellent prophylactic and therapeutic effect on systemic allergy reaction and topical skin allergy reaction by inhibiting generation of TNF-alpha, IL-6 and IL-8 in human cells with minimized side effects caused by long term medication. A method for preparing a composition for treating allergy comprises the steps of: (a) drying Vitis amurensis Ruprecht to have a moisture content of less than 15%; (b) after putting the dried Vitis amurensis Ruprecht in methanol in a weight ratio of 20-40:60-80, extracting it under reflux cooling; (c) concentrating the Vitis amurensis Ruprecht extract to recover the methanol; and (d) freeze-drying the concentrated Vitis amurensis Ruprecht to obtain a lyophilized Vitis amurensis Ruprecht extract. The method further comprises a step of mixing 1-90 wt.% of the lyophilized Vitis amurensis Ruprecht with 10-99 wt.% of a pharmaceutically acceptable carrier. Further, the composition for treating allergy is used in a form of oral, skin applying or injection medicine.

Description

Manufacturing method and composition of allergy treatment using the extract of the wild grapes {Manufacturing method and that creation water of the allergy treatment composition which uses the Vitis amurensis Ruprecht}

The present invention relates to a method for producing a composition for treating allergy using an extract of mule, and a composition thereof. More specifically, by citing an extract of mule extract that is safe and less toxic to the human body, the cell is prepared by oral preparation or formulation of skin coating. Method for the preparation of allergen compositions using the extract of Murus which shows excellent effects on the prevention and treatment of systemic allergic reactions and local skin allergic reactions through a mechanism of reducing the production of TNF-α, IL-6 and IL-8 in the And to the composition.

Allergies are generally systemic or localized disorders of living organisms based on immune responses that are the summation of a wide variety of complex pathological phenomena. Allergies present in the human body are classified into I, II, III and IV types according to the immune mechanism. Type I allergy, which is a type of immediate hypersensitivity reaction, is an important part of clinical practice, including atopic dermatitis, allergic rhinitis, bronchial asthma, hay fever and hay fever.

Type I allergy, as described above, is caused by activation of mast cells, and it is known in 1953 that granules of mast cells contain a large amount of histamine, a mediator of inflammation. Ishizaka's discovery of IgE during the discovery of histamine release from mast cells during an allergic reaction became an important opportunity to identify the mast cells involved in the immediate allergic reaction.

In other words, the surface of the mast cell has a high IgE affinity receptor, and when IgE binds to the receptor and then cross-links to form an antigen, degranulation reaction is induced, resulting in histamine (Histamine), serotonin (Serotonin), and Bradykinin ) this was synthesized stored mediators (Preformed mediator), protease (protease), proteoglycans (proteoglycan), etc., such as is emitted simultaneously (Ishizaka, etc., Histamine release from rat mast cells by antibodies against rat basophilic leukemia cell membrane. J. Immunol., 1977, 119: 1589-1596).

Since the 1970s, studies on new lipid-mediated inflammatory mediators have begun to be reported. These include prostaglandins, leukotriens, thromboxane, and glycerol produced from cell membrane phospholipids along with cell activation. As a newly generated mediator exhibiting various physiological activities, such as platelet activating factor (PAF), a derivative of glycosphospholipids, it has been found to be involved in various inflammatory reactions including type I allergic reactions. These lipid mediators are produced and released in parallel with degranulation in mast cells when IgE receptors form crosslinks.

In addition, cytokines well known as regulators of immune responses accompanied by activation of mast cells include IL-3 (mastocyte proliferation factor), IL-4, IL-5 (Galli SJ et al., Cytokine production by mast cells and basophils.Curr. Opin.Imunmun ., 1991, 3: 865-72, Bradding P et al., Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects.The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation.J. Immunol., 1993, 151: 3853-3865).

Allergic drugs currently being used in the clinic can be roughly classified into degranulation inhibitors, chemical transporter inhibitors, and chemical transporter inhibitors depending on the mechanism of action. Among these drugs, chemical transport inhibitors and chemical transport inhibitors have a relatively certain drug action point, but degranulation inhibitors have an unclear mechanism of action.

In addition, these drugs can cause various side effects by prolonged administration. Type I allergies include active amines and proteases, granule contents released by activation of mast cells, lipid mediators produced by membrane phospholipids, and cytokines produced by activation of transcription. It can be summarized as a natural phenomenon of living organisms.

For the treatment of type I allergy as described above, it can be said that the development of substances capable of elucidating the mechanism of action and production of these bioactive substances in mast cells and minimizing the side effects of long-term use is very important. Therefore, development of drugs that modulate the production and release of bioactive substances with certain mechanisms of action in mast cells would be a preventive and therapeutic agent for allergies.

The present invention is to solve the problems of the prior art as described above, systemic allergic reactions and the systemic allergic reaction through the extract of the melon function mechanism to reduce the production of TNF-α and IL-6 and IL-8 in the human cells and It is an object of the present invention to provide a method for producing an allergy treatment composition and a composition for treating allergic skin using the extract of Maru which is excellent in preventing and treating local skin allergic reactions and minimizing side effects due to long-term use.

In addition, the technique according to the present invention, as well as to prevent and treat systemic allergic reactions and local skin allergic reactions through allergic agents prepared by the formulation of oral, skin application and injection formulations containing the melon extract, as well as melon extract It can be used in various foods.

The present invention configured to achieve the above object is as follows. In other words, the method for producing a composition for treating allergy using the extract of the beet according to the present invention comprises the steps of: (a) drying the beech to less than 15% moisture content; (b) injecting dried muru through methanol in the process of step (a), wherein the ratio of dried muru to methanol is added at a ratio of 20 to 40:60 to 80 wt% to extract reflux with cooling in a methanol water bath; (c) recovering methanol by concentrating the reflux extract extracted from the reflux through the process of step (b); And (d) lyophilizing the concentrated muru extract through the process of step (c) to obtain a lyophilized muru extract.

The technique according to the present invention is a mixture of 1 to 90% by weight of the lyophilized beet extract obtained through the process of step (d) and 10 to 99% by weight of a pharmaceutically acceptable carrier, which can be used for oral, dermal application and injection preparations. It can be prepared in one formulation.

In a construction of another technique in the present invention, the carrier is at least one carrier selected from the group consisting of excipients, binders, lubricants, disintegrants, coatings, emulsifiers, suspensions, solvents, stabilizers, absorption aids, water for injection and isotonic agents. Can be.

The dosage of the composition for treating allergy prepared through the configuration as described above is preferably used in the amount of 500 ~ 2,000 mg / day based on the weight of the lyophilized extract.

On the other hand, the oral preparations described above may be prepared in granules, tablets or capsules, and the skin coating preparations may be prepared in creams or lotions.

The composition for treating allergies using the extract of the melon according to the present invention is prepared by a method for preparing the composition for treating allergies using the extract of melon as described above.

Hereinafter will be described in detail with respect to a method for producing a composition for treating allergy using the extract of the roe according to a preferred embodiment of the present invention and its composition.

First, the present inventors have studied to develop a therapeutic agent for systemic allergy and local skin allergy, and experimentally proved that muru exhibits an excellent inhibitory effect on systemic allergic reactions and local skin allergic reactions. The composition was completed.

Since the main component of the technology according to the present invention has been used as a medicine or food for a long time, it is known to be safe and less toxic to the human body, and is commonly used for neurological headache, anorexia, and fatigue recovery. In addition, such melon has a mechanism of action that reduces the production of TNF-α, IL-6 and IL-8, and has an excellent effect on the prevention and treatment of systemic allergic reactions and local skin allergic reactions.

Looking at the technology of the present invention, the method for producing a composition for treating allergy using the extract of the present invention comprises the steps of drying the dried fruit to 15% or less moisture, the step of refrigeration cooling extraction in methanol water bath by putting dried dried fruit into methanol, Reflux cooling The extracted extract is concentrated to recover methanol, and the concentrated extract is freeze-dried to obtain a lyophilized extract.

On the other hand, if the lyophilized buckwheat extract prepared by the above-described configuration and the pharmaceutically acceptable carrier is mixed at a predetermined composition ratio, it can be prepared in any one of oral, dermal application and injection formulation.

In the composition of the present invention as described above, when the dried muru is added to methanol, the ratio of dried muru and methanol is added to the dried muru at methanol in a ratio of 20 to 40:60 to 80% by weight, and the freeze-dried muru extract The composition ratio of the pharmaceutically acceptable carrier and the pharmaceutically acceptable carrier is 1 to 90% by weight of the lyophilized extract and 10 to 99% by weight of the pharmaceutically acceptable carrier.

Pharmaceutically acceptable carriers, which are mixed with the lyophilized beets extract in the composition of the composition for treating allergy using the extract of the present invention according to the present invention, but are not limited thereto, excipients, binders, lubricants, disintegrating agents, coating agents, emulsifiers And at least one carrier selected from the group consisting of suspending agents, solvents, stabilizers, absorption aids, water for injection and isotonic agents.

The composition for treating allergies according to the present invention may be formulated as oral, dermal and injectable preparations, with the formulation of oral formulations and the formulations of skin coatings more preferred. At this time, oral preparations may be exemplified as granules, tablets, capsules, and the like, and skin coating preparations may be exemplified as creams or lotions.

On the other hand, the dosage of the composition for treating allergy according to the present invention may vary depending on the age, sex and weight of the patient, but usually 500 to 2,000 mg / day is preferred.

In addition, the composition for treating allergy according to the present invention may be used in various foods, and foods to which the composition of the present invention may be added include, for example, tea, alcohol, beverages, cosmetics, health supplements, and the like. Can be used to treat warm-blooded animals such as dogs, rabbits and cats. In other words, when the lyophilized extract extracted by the manufacturing method according to the present invention is mixed with tea, liquor, beverages, cosmetics, health supplement foods at a certain ratio, it can be used in various foods.

When the lyophilized buckwheat extract prepared by the preparation method according to the present invention is mixed with a pharmaceutically acceptable carrier at a predetermined composition ratio to prepare a formulation of an oral preparation for allergy treatment, it may be prepared as a tablet, capsule, and granule. At this time, when preparing a tablet as a formulation of an oral preparation for allergy treatment, the composition ratio of the lyophilized buckwheat extract and the carrier is 100 parts by weight of the lyophilized buckwheat extract, the lactose 80 to 85 parts by weight, and the lyophilized buckwheat extract 0.5 to 1.0 parts by weight of talc and 0.05 to 0.2 parts by weight of magnesium stearate relative to the weight of the lyophilized extract.

And, when preparing a capsule as a formulation of oral preparations for the treatment of allergy, the composition ratio of the lyophilized buckwheat extract and the carrier is 100 parts by weight of the lyophilized buckwheat extract, 1 to 2 parts by weight of starch and lyophilized based on the weight of the lyophilized buckwheat extract. It is composed of a composition that is filled in gelatin capsules after mixing in a composition ratio of 10 to 20 parts by weight of magnesium stearate with respect to the weight of the extract.

In addition, in the preparation of granules as a formulation of oral preparations for the treatment of allergy, the composition ratio of the lyophilized buckwheat extract and the carrier is 100 parts by weight of the lyophilized buckwheat extract, 10-20 parts by weight of lactose and the lyophilized buckwheat It consists of a composition ratio of 0.5-1.0 weight part of talc with respect to the weight of an extract.

In addition, the technique according to the present invention is mixed with a pharmaceutically acceptable carrier and a predetermined composition ratio of the lyophilized extract extracted through the manufacturing method according to the invention in the case of preparing the formulation of the skin coating formulation for allergy treatment and cream and It may be prepared as a lotion agent. In this case, when preparing a cream as a formulation of a skin coating formulation for allergy treatment, the composition ratio of the lyophilized buckwheat extract and the carrier is 100 parts by weight of the lyophilized buckwheat extract, 450-550 parts by weight of white petrolatum with respect to the weight of the lyophilized buckwheat extract, Stearin alcohol 350-450 parts by weight relative to the weight of the lyophilized extract, 200-280 parts by weight of propylene glycol relative to the weight of the lyophilized extract, and 100-140 weight of monoglycerol stearic acid based on the weight of the lyophilized extract. 0.1,0.2 parts by weight of castor oil, 0.1 to 0.2 parts by weight of methyl paraben, and 600 to 650 parts by weight of purified water, based on the weight of lyophilized extract, Is done.

On the other hand, when the lotion is prepared as a formulation of the skin coating formulation for allergy treatment, the composition ratio of the lyophilized buckwheat extract and the carrier is 100 parts by weight of the lyophilized buckwheat extract, and 150 to 170 parts by weight of glycerin with respect to the weight of the lyophilized buckwheat extract, 30 to 50 parts by weight of oleic acid, 5 to 15 parts by weight of triethanolamine, and 1650 to 1700 parts by weight of purified water, based on the weight of the lyophilized meringue extract, based on the weight of the dried meringue extract.

In addition, the lyophilized beet extract prepared by the manufacturing method according to the present invention can be prepared in the formulation of an injection for treating allergy by mixing with a pharmaceutically acceptable carrier in a certain composition ratio. At this time, in the case of injection for allergy treatment, the composition ratio of the lyophilized buckwheat extract and the carrier is 100 parts by weight of the lyophilized buckwheat extract, 1.0-2.0 parts by weight of sodium sulfite acid, and the weight of the lyophilized buckwheat extract 0.5-1.5 parts by weight of methyl paraben, 0.3-1.0 parts by weight of furopenparaben, and 1.5-2.5 parts by weight of sodium phosphate monobasic, and lyophilized extract of mercury extract 1.0 to 1.5 parts by weight of sodium diphosphate, 1.0 to 2.0 parts by weight of sodium hydroxide relative to the weight of the lyophilized meringue extract, and 1.0 to 2.0 parts by weight of water for injection relative to the weight of the lyophilized meringue extract.

Hereinafter, the technology according to the present invention will be described in more detail with reference to Examples and Manufacturing Examples of the present invention. At this time, the present invention is not limited to the following examples and preparation examples.

Example 1

Preparation of Methanol Extract of Wild Fruits

After drying the medicinal herbs in a medicine drier, reflux extraction by attaching a reflux condenser in a methanol water bath of 70% by weight, concentrated to recover the methanol, and dried by a lyophilizer to prepare a freeze-dried maru extract.

Example 2

Effect of Concentrated Extract of Murume on Systemic Allergic Reaction

A mortality study was conducted to determine the effects of the buckwheat on systemic allergic reactions in mice. Table 1 shows the effect of the concentration of melon on systemic allergic reactions. 60 minutes before the degranulation of Compound 48/80 was injected into the abdominal cavity of mice, the dried muru was injected intraperitoneally at a dose of 0.005 to 0.1 mg / g and mortality was observed for 1 hour after inducing anaphylaxis. The control group treated with 200 μl of saline showed 100% mortality, but the mortality rate was 80% when 0.01 mg / g was administered and 20% and 0.05 mg / g when 0.05 mg / g was administered. The mortality was suppressed in concentration-dependent manner at 0%.

Table showing the effect of the concentration of the extract on systemic allergic reactions Maroon (mg / g, BW) compound 48/80 (0.008 mg / g BW) mortality (%) none (saline) + 100 0.005 + 100 0.01 + 80 0.05 + 20 0.1 + 0 0.1 - 0

Example 3

Effects of Muru extracts over Time on Systemic Allergic Reactions

The mortality test was conducted over time to determine the effect of the extract of Murume on systemic allergic reactions in mice. Table 2 shows the effects over time of the extract of the wild grapes on the systemic allergic reaction. Degranulation compound 48/80 was administered to the abdominal cavity of mice, and 0.1 mg / g of lyophilized wild berry extract was injected intraperitoneally at 5 minutes, 10 minutes, 15 minutes, and 20 minutes, respectively. The lethality was 1 hour after inducing anaphylaxis. Was observed. Mortality increased by 0% when 5 minutes after degranulation of Compound 48/80 in mice intraperitoneally, 40% after 10 minutes, and 80% after 15 minutes. I could see.

Table showing the effects of Murume extract over time on systemic allergic reactions Maroon (mg / g, BW) time (min) compound 48/80 (0.008 mg / g BW) mortality (%) none (saline) 0 + 100 0.1 5 + 0 10 + 40 15 + 80 20 + 100

Example 4

Effects of Extracts of Muru on Local Skin Allergic Reactions

Passive cutaneous anaphylaxis (PCA), which is widely used in the development of drugs with allergic effects, was used to test the effects of extracts on skin allergy. PCA is an experimental method in which an allergic reaction mediated by immunoglobulin E is injected intravenously into topical skin, and then an antigen is injected into the tail vein of a mouse artificially to cause an allergic reaction 48 hours later. Table 3 shows the effect of the fern extract on the topical skin allergic reaction. When antigen and antibody are administered to mice, local redness occurs at the site of antibody injection, thereby activating mast cells present at the site, thereby causing an allergic reaction locally. As a result of pretreatment of the extract, it was found that the extract suppressed the local skin allergic reaction in a concentration-dependent manner.

Table showing the effect of the extract of the wild grape on the topical skin allergic reaction Maroon (mg / g) Anti-DNP IgE plus DNP_HSA Inhibition (%) none (saline) + 0.001 + 17.7 0.01 + 21.3 0.1 + 52.1 ^* One + 58.8 ^*

Example 5

Effects of Extracts of Murano on Secretion of Inflammatory Cytokines

Inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) are important bioactive substances that cause inflammatory allergies by being released from the mast cells or newly synthesized. Table 4, Table 5 and Table 6 show the effect of Murume extract on the secretion of proinflammatory cytokines.

Phorbol 12-myristate 13-acetate (PMA), a protein kinase C activator, and Calcium ionophore A23187 (A23187), a calcium channel activator, are known to activate mast cells to promote secretion of inflammatory cytokines. Administration of cells to human mast cell lime (HMC-1) resulted in increased tumor necrosis factor-alpha, interleukin-6 and interleukin-8 secretion. In addition, as a result of pretreatment of the extracts by concentration, the extracts reduced tumor necrosis factor-alpha, interleukin-6 and interleukin-8 secretion by PMA and A23187.

Table showing the effect of the extract of Murhu on the secretion of proinflammatory cytokine TNF-α Treatment Concentration (mg / ml) TNF-α content (ng / ml) none (saline) 0.639 ± 0.041 PMA + A23187 (control) 2.334 ± 0.088 PMA + A23187 + Maroo 0.01 2.035 ± 0.024 PMA + A23187 + Maroo 0.1 1.434 ± 0.074 ^* PMA + A23187 + Maroo One 1.168 ± 0.035 ^*

Table showing the effect of the extract of Murhu on the secretion of proinflammatory cytokine IL-6 Treatment Concentration (mg / ml) IL-6 content (ng / ml) none (saline) 0.074 ± 0.020 PMA + A23187 (control) 0.214 ± 0.031 PMA + A23187 + Maroo 0.01 0.197 ± 0.043 PMA + A23187 + Maroo 0.1 0.149 ± 0.031 ^* PMA + A23187 + Maroo One 0.131 ± 0.012 ^*

Table showing the effect of the extract of Murhu on the secretion of proinflammatory cytokine IL-8 Treatment Concentration (mg / ml) IL-8 content (ng / ml) none (saline) 0.213 ± 0.041 PMA + A23187 (control)  2.726 ± 0.550 PMA + A23187 + Maroo 0.01  2.420 ± 0.173 PMA + A23187 + Maroo 0.1  2.364 ± 0.241 PMA + A23187 + Maroo One 1.407 ± 0.151 ^*

Hereinafter, the preparation examples of the composition for treating allergy according to the present invention in various dosage forms will be described.

[Production Example 1] Tablet

According to the following composition to prepare a tablet by a conventional tablet manufacturing method.

Tablet composition

Lyophilized Maroon Extract ------------------------ 600.0 mg

Lactose -------------------------------------- 500.0 mg

Talc ----------------------------------------- 5.0 mg

Magnesium Stearate ------------------------ 1.0 mg

[Production Example 2] Capsule

A capsule was prepared by a conventional capsule preparation method through the composition as follows. At this time, the lyophilized buckwheat extract was sieved, mixed with an excipient, and filled into gelatin capsules to prepare capsules.

Capsule Composition

Lyophilized Maroon Extract ------------------------ 600.0 mg

Starch 1500 ----------------------------------- 10.0 mg

Magnesium Stearate ------------------------- 100.0 mg

Production Example 3 Granules

A granule was prepared by a conventional granule preparation method through the composition as follows.

Granule composition

Lyophilized Maroon Extract ------------------------ 600.0 mg

Lactose -------------------------------------- 100.0 mg

Talc ----------------------------------------- 5.0 mg

Production Example 4 Injection

Injectables were prepared by a conventional method for preparing injectables through the following composition.

Injectable Composition

Lyophilized Maroon Extract ------------------------ 600.0 mg

Sodium acid sulfite ---------------------------- 10.0 mg

Methylparaben ----------------------------------- 6.0 mg

Fufenparaben --------------------------------- 4.0 mg

Sodium monophosphate ------------------------------ 12.0 mg

Sodium Diphosphate ------------------------------- 8.0 mg

Sodium Hydroxide -------------------------------- 10.0 mg

Water for Injection ------------------------------------ 10.0 ml

Production Example 5 Cream

The following components were used to prepare a cream by the usual cream preparation.

Cream composition

Lyophilized Maroon Extract ------------------------- 50.0 g

White Vaseline --------------------------------- 250.0 g

Stearin Alcohol ----------------------------- 200.0 g

Propylene glycol --------------------------- 120.0 g

Stearic Acid Monoglycerine ---------------------- 60.0 g

Castor Oil ------------------------------------- 0.08 g

Methylparaben ----------------------------------- 0.06 g

Purified Water ------------------------------------- 319.86 g

[Manufacture example 6] lotion system

The following components were used to prepare the lotion by the usual method of preparing the lotion.

Lotion composition

Lyophilized Maroon Extract ------------------------- 50.0 g

Glycerin ------------------------------------- 80.0 g

Oleic acid ------------------------------------- 20.0 g

Triethanolamine -------------------------------- 5.0 g

Purified water -------------------------------------- 845 g

As described above, the technique according to the present invention can prevent and treat systemic allergic reactions and local skin allergic reactions through allergic agents prepared by the formulation of oral, skin application and injection preparations containing the melon extract.

The present invention is not limited to the above embodiments, and various modifications can be made within the scope of the technical idea of the present invention.

As described above, according to the present invention, the effect of preventing and treating systemic allergic reactions and local skin allergic reactions through the extract of melon which has a mechanism of action that reduces the production of TNF-α and IL-6 and IL-8 in human cells. The effect of providing an allergy therapeutic agent prepared in the formulation of oral, dermal application and injectable preparations is excellent while minimizing the side effects of long-term use.

In addition, the technique according to the present invention, as well as to prevent and treat systemic allergic reactions and local skin allergic reactions through allergic agents prepared by the formulation of oral, skin application and injection formulations containing the melon extract, as well as melon extract It can also be used for a variety of foods, such as tea, alcohol, beverages, cosmetics, dietary supplements.

Claims (6)

(a) drying the mulberry to 15% or less of moisture; (b) injecting dried muru through methanol in the process of step (a), wherein the ratio of dried muru to methanol is added at a ratio of 20 to 40:60 to 80 wt% to extract reflux with cooling in a methanol water bath; (c) recovering methanol by concentrating the reflux extract extracted from the reflux through the process of step (b); And (D) a method for producing a composition for treating allergy using an extract of buckwheat, comprising a step of lyophilizing the concentrated buckwheat extract through the process of step (c) to obtain a lyophilized buckwheat extract. According to claim 1, wherein the composition of the oral, dermal application and injection formulation by mixing in a composition ratio of 1 to 90% by weight of the lyophilized extract of the extract obtained through the step (d) and 10 to 99% by weight of a pharmaceutically acceptable carrier Method for producing a composition for treating allergy using the extract of the melon, characterized in that it is prepared in any one formulation. 3. The carrier according to claim 2, wherein the carrier is at least one carrier selected from the group consisting of excipients, binders, lubricants, disintegrants, coating agents, emulsifiers, suspensions, solvents, stabilizers, absorption aids, water for injection and isotonic agents. Method for producing a composition for the treatment of allergy using the extract of the melon, characterized in that. The method of claim 2, wherein the dosage of the composition for treating allergy is 500 to 2,000 mg / day based on the weight of the lyophilized extract of the extract. The method of claim 2, wherein the oral preparation is made of granules, tablets or capsules, and the skin coating preparation is made of a cream or lotion. Claims 1 to 5, wherein the composition for the treatment of allergies using the extract of any one of the preceding, characterized in that it is prepared.